256951-82-3

Basic information

• Product Name: Benzeneacetonitrile, 2-cyano-4-fluoro- (9CI)
• Synonyms: Benzeneacetonitrile, 2-cyano-4-fluoro- (9CI);2-Cyano-4-fluorobenzeneacetonitrile
• CAS NO: 256951-82-3
• Molecular Formula: C₉H₅FN₂
• Molecular Weight: 160.1478032
• Product Categories: HALIDE
• Mol File: 256951-82-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzeneacetonitrile, 2-cyano-4-fluoro- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzeneacetonitrile, 2-cyano-4-fluoro- (9CI)(256951-82-3)
• EPA Substance Registry System: Benzeneacetonitrile, 2-cyano-4-fluoro- (9CI)(256951-82-3)

Safety Data

• Hazardous Substances Data: 256951-82-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Benzeneacetonitrile, 2-cyano-4-fluoro(9CI), is utilized as an intermediate in the synthesis of various pharmaceutical compounds. Its unique structure and reactivity contribute to the development of new drugs with specific therapeutic properties.
Used in Pesticide Industry:
In the pesticide industry, Benzeneacetonitrile, 2-cyano-4-fluoro(9CI), serves as a key component in the formulation of certain pesticides. Its chemical properties allow for the creation of effective pest control agents that target specific pests while minimizing harm to the environment and non-target organisms.
Used in Organic Compounds Synthesis:
Benzeneacetonitrile, 2-cyano-4-fluoro(9CI), is employed as a building block in the synthesis of various organic compounds. Its versatility and reactivity make it a valuable asset in the development of new materials with specific chemical and physical properties for use in different industries.

Upstream product

• 64248-64-2 2,5-difluorobenzonitrile 
• 105-34-0 methyl 2-cyanoacetate 
• 105-56-6 ethyl 2-cyanoacetate 
• 1116-98-9 cyanoacetic acid tert-butyl ester 

Downstream Products

• 1425605-95-3 7-fluoro-3-phenylisoquinolin-1-amine 
• 256951-84-5 1-(3-N-bocaminopropyl)-4-cyano-4-(2-cyano-4-fluorophenyl)-piperidine 
• 265985-79-3 4-cyano-4-(2-cyano-4-fluorophenyl)piperidine 
• 256951-83-4 4-cyano-4-(2-cyano-4-fluorophenyl)piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Nickel-Catalyzed Tandem Reaction of Functionalized Arylacetonitriles with Arylboronic Acids in 2-MeTHF: Eco-Friendly Synthesis of Aminoisoquinolines and Isoquinolones

The first example of the nickel-catalyzed tandem addition/cyclization of 2-(cyanomethyl)benzonitriles with arylboronic acids in 2-MeTHF has been developed, which provides the facile synthesis of aminoisoquinolines with good functional group tolerance under mild conditions. This chemistry has also been successfully applied to the synthesis of isoquinolones by the tandem reaction of methyl 2-(cyanomethyl)benzoates with arylboronic acids. The use of the bio-based and green solvent 2-MeTHF as the reaction medium makes the synthesis process environmentally benign. The synthetic utility of this chemistry is also indicated by the synthesis of biologically active molecules.

Regioselective Access to 3-Aryl-1-aminoisoquinolines via Nickel(I)-Catalyzed C-C and C-N Cascade Coupling Reactions from the Substituted 2-(Cyanomethyl)benzonitriles

A novel and regioselective Ni(I) catalyzed C-C and C-N cascade coupling reactions has been developed. The cascade furnishes atom-economic access to 40 3-aryl-1-aminoisoquinolines. The regioselectivity of C(sp3)-cyano group over C(sp2

ANTIBACTERIAL COMPOUNDS HAVING BROAD SPECTRUM OF ACTIVITY

The present invention relates to novel antibacterial compounds, pharmaceutical compositions containing them and their use as antimicrobials.

Alpha 1A adrenergic receptor antagonists

This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as alpha 1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.

Dihydropyridinones and pyrrolinones useful as alpha 1A adrenoceptor antagonists

Novel dihydropyridinone and pyrrolinone compounds and pharmaceutically acceptable salts thereof are disclosed. The synthesis of these compounds and their use as alpha1aadrenergic receptor antagonists is also described. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha1areceptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia can be achieved.

In vitro, and in vivo, evaluation of dihydropyrimidinone C-5 amides as potent and selective α(1A) receptor antagonists for the treatment of benign prostatic hyperplasia

α1 Adrenergic receptors mediate both vascular and lower urinary tract tone, and α1 receptor antagonists such as terazosin (1b) are used to treat both hypertension and benign prostatic hyperplasia (BPH). Recently, three different subtypes of this receptor have been identified, with the α(1A) receptor being most prevalent in lower urinary tract tissue. This paper explores 4-aryldihydropyrimidinones attached to an aminopropyl-4- arylpiperidine via a C-5 amide as selective α(1A) receptor subtype antagonists. In receptor binding assays, these types of compounds generally display K(i) values for the α(1a) receptor subtype 20%) and half-life (>6 h) in both rats and dogs. Due to its selectivity for the α(1a) over the α(1b) and α(1d) receptors as well as its favorable pharmacokinetic profile, 48 has the potential to relieve the symptoms of BPH without eliciting effects on the cardiovascular system.